Sökning: WFRF:(Teraa M.) > Management of Cardi...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03651naa a2200493 4500 | |
001 | oai:lup.lub.lu.se:55394e60-a904-4005-9a34-84a3885a18fc | |
003 | SwePub | |
008 | 160401s2011 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/23484072 URI |
024 | 7 | a https://doi.org/10.1016/S1078-5884(11)60011-72 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Diehm, N.4 aut |
245 | 1 0 | a Management of Cardiovascular Risk Factors and Medical Therapy |
264 | 1 | c 2011 |
520 | a Critical limb ischaemia (CLI) is a particularly severe manifestation of lower limb atherosclerosis posing a major threat to both limb and life of affected patients. Besides arterial revascularisation, risk-factor modification and administration of antiplatelet therapy is a major goal in the treatment of CLI patients. Key elements of cardiovascular risk management are smoking cessation and treatment of hyperlipidaemia with dietary modification or statins. Moreover, arterial hypertension and diabetes mellitus should be adequately treated. In CLI patients not suitable for arterial revascularisation or subsequent to unsuccessful revascularisation, parenteral prostanoids may be considered. CLI patients undergoing surgical revascularisation should be treated with beta blockers. At present, neither gene nor stem-cell therapy can be recommended outside clinical trials. Of note, walking exercise is contraindicated in CLI patients due to the risk of worsening pre-existing or causing new ischaemic wounds. CLI patients are oftentimes medically frail and exhibit significant comorbidities. Co-existing coronary heart and carotid as well as renal artery disease should be managed according to current guidelines. Considering the above-mentioned treatment goals, interdisciplinary treatment approaches for CLI patients are warranted. Aim of the present manuscript is to discuss currently existing evidence for both the management of cardiovascular risk factors and treatment of co-existing disease and to deduct specific treatment recommendations. (C) 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kirurgi0 (SwePub)302122 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Surgery0 (SwePub)302122 hsv//eng |
653 | a Conservative treatment | |
653 | a Medication | |
653 | a Risk factor modification | |
700 | 1 | a Schmidli, J.4 aut |
700 | 1 | a Setacci, C.4 aut |
700 | 1 | a Ricco, J. -B.4 aut |
700 | 1 | a de Donato, G.4 aut |
700 | 1 | a Becker, F.4 aut |
700 | 1 | a Robert-Ebadi, H.4 aut |
700 | 1 | a Cao, P.4 aut |
700 | 1 | a Eckstein, H. H.4 aut |
700 | 1 | a De Rango, P.4 aut |
700 | 1 | a Teraa, M.4 aut |
700 | 1 | a Moll, F. L.4 aut |
700 | 1 | a Dick, F.4 aut |
700 | 1 | a Davies, A. H.4 aut |
700 | 1 | a Lepantalo, M.4 aut |
700 | 1 | a Apelqvist, Janu Lund University,Lunds universitet,Genomik, diabetes och endokrinologi,Forskargrupper vid Lunds universitet,Genomics, Diabetes and Endocrinology,Lund University Research Groups4 aut0 (Swepub:lu)endo-jap |
710 | 2 | a Genomik, diabetes och endokrinologib Forskargrupper vid Lunds universitet4 org |
773 | 0 | t European Journal of Vascular and Endovascular Surgeryg 42:Suppl. 2, s. 33-42q 42:Suppl. 2<33-42x 1532-2165 |
856 | 4 | u http://dx.doi.org/10.1016/S1078-5884(11)60011-7y FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/2348407 |
856 | 4 8 | u https://doi.org/10.1016/S1078-5884(11)60011-7 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.